Brokerages expect that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will report $88.02 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $84.15 million to $92.17 million. Supernus Pharmaceuticals reported sales of $62.37 million in the same quarter last year, which indicates a positive year-over-year growth rate of 41.1%. The firm is expected to report its next quarterly earnings report on Tuesday, February 27th.

On average, analysts expect that Supernus Pharmaceuticals will report full-year sales of $88.02 million for the current fiscal year, with estimates ranging from $294.60 million to $305.98 million. For the next year, analysts anticipate that the business will post sales of $393.97 million per share, with estimates ranging from $385.13 million to $404.56 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business’s revenue was up 41.5% compared to the same quarter last year.

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Janney Montgomery Scott reissued a “hold” rating and issued a $47.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Piper Jaffray Companies reissued a “hold” rating and issued a $45.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. Cowen set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, Jefferies Group reissued a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $50.00.

Shares of Supernus Pharmaceuticals (SUPN) traded up $1.25 during trading on Thursday, hitting $41.70. 496,400 shares of the company’s stock traded hands, compared to its average volume of 518,050. The company has a market cap of $2,040.00, a PE ratio of 37.91 and a beta of 1.17. Supernus Pharmaceuticals has a 52 week low of $23.10 and a 52 week high of $50.04.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 2,220 shares during the period. Riverhead Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 91.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 1,462 shares during the period. Advisor Group Inc. boosted its stake in Supernus Pharmaceuticals by 13.7% in the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after purchasing an additional 410 shares during the period. Victory Capital Management Inc. boosted its stake in Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after purchasing an additional 517 shares during the period. Finally, Flinton Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 88.9% in the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after purchasing an additional 2,240 shares during the period. 98.22% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/04/supernus-pharmaceuticals-inc-supn-expected-to-post-quarterly-sales-of-88-02-million.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.